Evidence Scope
These research surveys include evidence ranging from established human data to preclinical research and biological extrapolation. The language used is intended to reflect the strength of that evidence.
Mechanistic evidence is not treated as equivalent to clinical evidence, but it is also not dismissed simply because large human trials are unavailable. Mechanistically supported extrapolation may be appropriate when the underlying biology is credible and the strength of the language matches the evidence.
Evidence may include:
In vitro or ex vivo studies, which can establish biological activity or a potential mechanism but may not translate to effects in a living organism.
Animal studies, which can support biological plausibility and demonstrate effects in vivo, while leaving uncertainty about their applicability to humans.
Observational or small human studies, including pilot and early-phase trials, which can provide preliminary evidence in humans but may be limited by sample size, study design, lack of replication, or reliance on surrogate outcomes.
Larger, well-controlled human trials and consistent clinical evidence, which can support stronger conclusions about efficacy, safety, and clinical relevance.
The evidentiary weight of a study depends on its quality, design, relevance, replication, effect size, and consistency with the broader evidence, not solely on whether it is in vitro, animal, or human research.
For combinations, complementary mechanisms may justify describing an additive or synergistic effect as possible or plausible, but not as established unless the combination itself has been tested. Evidence for the individual components cannot, by itself, demonstrate that their combined effects are additive or synergistic.
Evidence may be downgraded when important limitations reduce confidence. Human evidence does not automatically warrant a “likely” or unqualified conclusion. Less weight may be assigned when findings come primarily from small or poorly described studies, a narrow regional research literature, occupational or population studies rather than trials of the compound itself, inaccessible or incompletely reported publications, or researchers and institutions involved in developing or promoting the compound. Findings may also be downgraded when they lack appropriate controls, use surrogate outcomes, have not been independently replicated, or cannot be clearly attributed to the compound being evaluated.
Evidence Scopes from Weakest to Strongest
Speculative — A biological hypothesis with limited direct supporting evidence. Speculative benefits are generally omitted unless they are discussed frequently enough within peptide communities that addressing them would help distinguish community claims from established evidence. When included, they are clearly identified as substantially uncertain and may be based primarily on theoretical mechanisms, anecdotal reports, computational modeling, or isolated in vitro findings that have not been replicated or supported in vivo.
Plausible / Possible — Supported by relevant preclinical, mechanistic, or limited human evidence. The extrapolation is biologically reasonable, but the proposed effect has not been demonstrated with enough evidence to consider it probable. Examples might include replicated in vitro findings, relevant animal studies, biomarker evidence, observational human data, case series, or a small pilot trial.
Likely / Probable — Supported by stronger, reasonably consistent evidence suggesting that the effect is more likely than not, although meaningful uncertainty remains. Examples might include multiple convergent animal and human studies, replicated observational findings, or one or more reasonably designed human trials whose size, duration, population, or outcomes limit the certainty of the conclusion.
No qualification — Used when the statement is sufficiently well established by the totality of the available evidence. This will generally require consistent findings from adequately powered, well-controlled human trials, supported where appropriate by systematic reviews, meta-analyses, or broad clinical consensus. Large-scale trials alone are not necessarily sufficient if their findings are inconsistent, methodologically weak, or not directly applicable to the claim.
Editorial Designation
★ Researcher6076’s Pick
A personal editorial designation reflecting the author’s interest in or favorable opinion of a peptide. It is not regulatory approval, medical advice, a treatment recommendation, or an evidence rating, and it does not override the card’s safety or effectiveness assessments.